Halozyme, Inc.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
6
Ending by 2030
Sep 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Sep 8 to 15, 2027 · next Sep 8
- 1 fee due Oct 9, 2027The maintenance fee for PH20 Polypeptide Variants, Formulations and Uses Thereof (US 11,952,600) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
- 1 fee due Nov 10, 2027The maintenance fee for Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia (US 9,333,244) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,767,429 | Soluble Hyaluronidase Glycoprotein (SHASEGP), Process for Preparing the Same, Uses and Pharmaceutical Compositions Comprising Thereof In force · High confidence | In force | High confidence | |
| US 7,871,607 | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases In force · Medium confidence | In force | Medium confidence | |
| US 8,187,855 | Large-Scale Production of Soluble Hyaluronidase In force · High confidence | In force | High confidence | |
| US 8,343,487 | Large-Scale Production of Soluble Hyaluronidase In force · High confidence | In force | High confidence | |
| US 9,775,889 | Methods of Treatment of Cellulite In force · Medium confidence | In force | Medium confidence | |
| US 9,833,498 | Methods of Treatment of Collagen-Mediated Diseases and Conditions In force · Medium confidence | In force | Medium confidence | |
| US 9,284,543 | Neutral Active Soluble Truncated PH20 Polypeptides and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,265,410 | Adverse Side-Effects Associated with Administration of an Anti-Hyaluronan Agent and Methods for Ameliorating or Preventing the Side-Effects In force · High confidence | In force | High confidence | |
| US 8,927,249 | Extended Soluble PH20 Polypeptides and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,018,298 | PH20 Polypeptide Variants, Formulations and Uses Thereof In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 48: 3 patents in force now held by others · 16 lapsed for an unpaid fee · 22 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
14 pending · 14 abandoned · 5 no status recorded